<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2709-7927</journal-id>
<journal-title><![CDATA[Acta Médica del Centro]]></journal-title>
<abbrev-journal-title><![CDATA[Acta méd centro]]></abbrev-journal-title>
<issn>2709-7927</issn>
<publisher>
<publisher-name><![CDATA[Hospital Provincial Clínico Quirúrgico Universitario Arnaldo Milián Castro]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2709-79272023000200262</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Estudio clínico-patológico de los subtipos luminales en el carcinoma mamario]]></article-title>
<article-title xml:lang="en"><![CDATA[Clinic-pathological study of the luminal subtypes in the breast carcinoma]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Pérez]]></surname>
<given-names><![CDATA[Raisel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Llanes García]]></surname>
<given-names><![CDATA[Llanuris]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Borrego Gutiérrez]]></surname>
<given-names><![CDATA[Disney]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguado Besú]]></surname>
<given-names><![CDATA[Yunexy]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez Hernández]]></surname>
<given-names><![CDATA[Leticia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Franco Rodón]]></surname>
<given-names><![CDATA[Alicia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas de Villa Clara  ]]></institution>
<addr-line><![CDATA[Santa Clara Villa Clara]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario &#8220;Celestino Hernández Robau&#8221;  ]]></institution>
<addr-line><![CDATA[Santa Clara Villa Clara]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<volume>17</volume>
<numero>2</numero>
<fpage>262</fpage>
<lpage>274</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S2709-79272023000200262&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S2709-79272023000200262&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S2709-79272023000200262&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  la mayoría de los carcinomas de mama expresan receptores hormonales, lo que traduce una mejor respuesta a la terapia endocrina.  Objetivo:  determinar la incidencia de los subtipos luminales en los carcinomas mamarios diagnosticados en el Hospital &#8220;Celestino Hernández&#8221; y su relación con variables clínico-patológicas clásicas de valor pronóstico.  Métodos:  estudio retrospectivo, de corte transversal, realizado en el Hospital &#8220;Celestino Hernández&#8221; en el período comprendido de enero de 2017 a mayo de 2019. Se incluyeron 281 mujeres con diagnóstico histológico de carcinoma mamario infiltrante y estudio inmunohistoquímico realizado. Se determinó la incidencia de los subtipos luminales A y B y la relación de cada uno con las variables: edad, talla tumoral, tipo y grado histológicos. Se determinó el índice de proliferación para los tumores luminal B.  Resultados:  el subtipo molecular luminal B del carcinoma mamario tuvo una mayor incidencia. En ambos subtipos luminales más de las dos terceras partes de las pacientes fueron mayores de 50 años, más del 60% tuvieron histología no especial y similar proporción estuvieron asociadas a variantes histológicas moderadamente diferenciadas del carcinoma mamario. Las lesiones poco diferenciadas y las tallas mayores de 2 cm se informaron con mayor incidencia en el subtipo luminal B y más del 90% de los tumores con ese subtipo molecular presentaron un índice de proliferación elevado. Hubo asociación estadísticamente significativa entre el grado tumoral y los subtipos moleculares.  Conclusiones:  el subtipo molecular luminal B presentó características clínicas e histopatológicas que traducen un comportamiento biológico más agresivo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  the majority of breast carcinomas subtype are positive to the expression of hormone receptors which is associated to a good response to the endocrine therapy.  Objective:  to determine the incidence of the luminal subtypes luminal A diagnosed at the Teaching University Hospital Celestino Hernández, Villa Clara and its correlation with classical prognostic value clinic-pathological variables.  Methods:  a retrospective, cross-sectional study was carried out at the Hospital Celestino Hernández of the period from January 2017 to June 2019. The research included 281 women with diagnosis of infiltrating breast carcinoma, whose biopsies were studied by immunohistochemistry. It was determined the incidence of the luminal subtypes luminal A and B and their correlation with the variables: age, location, tumor size, histologic type and histologic grade. The proliferation index was determined for luminal B tumors.  Results:  the molecular subtype luminal B had a higher incidence. In both luminal subtypes more than two third of patients were older than 50 years old, more than 60 % had no special histology tumors and similar percentage were associated to moderately histological types of breast carcinoma. The poorly-differentiated tumoral lesions and the tumor size larger than 2 cm was reported with higher incidence in luminal B tumors and more than 90 % of tumors of that molecular subtype had a high proliferation index.  Conclusions:  the molecular subtype luminal B had clinic and histological features that render a more aggressive biological behavior.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[neoplasia de la mama]]></kwd>
<kwd lng="es"><![CDATA[estudio inmunohistoquímco]]></kwd>
<kwd lng="es"><![CDATA[subtipos luminales]]></kwd>
<kwd lng="en"><![CDATA[breast neoplasms]]></kwd>
<kwd lng="en"><![CDATA[immunohistochemistry study]]></kwd>
<kwd lng="en"><![CDATA[luminal subtypes]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valle-Solís]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Miranda-Aguirre]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Mora-Pérez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pineda-Juárez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Gallardo-Valencia]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Santana]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Supervivencia en cáncer de mama por subtipo mediante inmunohistoquímica: Un estudio retrospectivo]]></article-title>
<source><![CDATA[Gac Med Mex]]></source>
<year>2019</year>
<volume>155</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S50-5</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bolaño Guerra]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Orihuela]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Soto-Pérez-de-Celis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Chávarri-Guerra]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Historia de los receptores hormonales y de la terapia hormonal en cáncer de mama]]></article-title>
<source><![CDATA[Medicina]]></source>
<year>2021</year>
<volume>43</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>189-207</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez Navarro]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Socorro Castro]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inmunohistoquímica en el cáncer de mama. Herramienta necesaria en la actualidad]]></article-title>
<source><![CDATA[Medisur]]></source>
<year>2018</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>209-13</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<collab>Union for International Cancer Control (UICC)</collab>
<source><![CDATA[Globocan 2020: New Global Cancer Data]]></source>
<year>16/0</year>
<month>1/</month>
<day>20</day>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[UICC]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública. Dirección Registros Médicos y Estadísticas de Salud</collab>
<source><![CDATA[Anuario estadístico de Salud 2020]]></source>
<year>2021</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[MINSAP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arrechea Irigoyen]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Vicente García]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Córdoba Iturriagagoitia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ibáñez Beroiz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Santamaría Martínez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Guillén Grima]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subtipos moleculares del cáncer de mama: implicaciones pronósticas y características clínicas e inmunohistoquímicas]]></article-title>
<source><![CDATA[Anales Sis San Navarra]]></source>
<year>2011</year>
<volume>34</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>219-33</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramírez-Torres]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Maycotte-González]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rivas-Ruíz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación de la clasificación molecular por inmunohistoquímica en cáncer de mama avanzado tratado con epirubicina y docetaxel: diferencias clínicas, patológicas, terapéuticas y pronósticas]]></article-title>
<source><![CDATA[Gac Mex Oncol]]></source>
<year>2018</year>
<volume>17</volume>
<page-range>15-27</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lamb]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Vanzulli]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
<name>
<surname><![CDATA[Lanari]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Receptores hormonales en cáncer de mama: receptores de estrógenos y algo más]]></article-title>
<source><![CDATA[Medicina (B. Aires)]]></source>
<year>2019</year>
<volume>79</volume>
<numero>6/1 Número Especial</numero>
<issue>6/1 Número Especial</issue>
<page-range>540-5</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<collab>Programa Nacional de Consensos Inter-Sociedades</collab>
<article-title xml:lang=""><![CDATA[Factores pronósticos y predictivos en cáncer de mama temprano]]></article-title>
<source><![CDATA[Rev Argent Mastol]]></source>
<year>2016</year>
<volume>36</volume>
<numero>128</numero>
<issue>128</issue>
<page-range>12-33</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alcaide Lucena]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez González]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[de Reyes Lartategui]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gallart Aragón]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Barrón]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[García Rubio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clasificación actual del cáncer de mama. Implicación en el tratamiento y pronóstico de la enfermedad]]></article-title>
<source><![CDATA[Cir Andal]]></source>
<year>2021</year>
<volume>32</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>155-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández-Tortolero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Reigosa-Yániz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subtipos del carcinoma luminal de mama según el consenso de Saint Gallen en un grupo de pacientes venezolanas]]></article-title>
<source><![CDATA[Biomed]]></source>
<year>2021</year>
<volume>41</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>531-40</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cserni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Histological type and typing of breast carcinomas and they WHO classification changes over time]]></article-title>
<source><![CDATA[Pathologica]]></source>
<year>2020</year>
<volume>112</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>25-41</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Abbas]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Aster]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<source><![CDATA[Robbins Basic Pathology]]></source>
<year>2013</year>
<edition>9</edition>
<publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier Saunders]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mayanga Sausa]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características clínico patológicas del cáncer de mama asociadas a la expresión del marcador celular Ki-67 en el Hospital Nacional Edgardo Rebagliati Martins, 2013-2017]]></article-title>
<source><![CDATA[An Fac Med]]></source>
<year>2019</year>
<volume>80</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>427-31</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramírez Valle]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[García Montesino]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lores Hechevarria]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Azcuy]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Márquez Hernández]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Histología e inmunohistoquímica del cáncer de mama invasivo en la provincia de Pinar del Río]]></article-title>
<source><![CDATA[Rev Ciencias Médicas]]></source>
<year>2019</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>71-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salazar Cifuentes]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Estrada Maldonado]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aplicación actual de la clasificación inmunohistoquímica de cáncer de mama]]></article-title>
<source><![CDATA[Rev Guatem Cir]]></source>
<year>2017</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hashmi]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Aijaz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Mahboob]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Irfan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zafar]]></surname>
<given-names><![CDATA[NI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic parameters of luminal A and luminal B intrinsic breast cáncer subtypes of Pakistani patients]]></article-title>
<source><![CDATA[World J Surg Oncol]]></source>
<year>2018</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Medina Bueno]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características clínicas y pronósticas de los subtipos moleculares de cáncer de mama determinados por inmunohistoquímica. Arequipa, Perú]]></article-title>
<source><![CDATA[Rev Perú Med Exp Salud Pública]]></source>
<year>2017</year>
<volume>34</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>472-7</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ulloa Ochoa]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ronquillo Torresano]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Pincay]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sobrevida en pacientes con cáncer de mama según su inmunohistoquímica experiencia del Instituto Oncológico Nacional-Sociedad de Lucha Contra el Cáncer, Guayaquil, Ecuador]]></article-title>
<source><![CDATA[Rev Méd Sinergia]]></source>
<year>2020</year>
<volume>5</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Erber]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hartmann]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Histology of luminal breast cancer]]></article-title>
<source><![CDATA[Breast Care (Basel)]]></source>
<year>2020</year>
<volume>15</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>327-36</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chico Urbina]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
</person-group>
<source><![CDATA[Implicaciones pronósticas de los subtipos moleculares por inmunohistoquímica de cáncer de mama en el Hospital de Especialidades Eugenio Espejo, Unidad de Mastología]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Quito ]]></publisher-loc>
<publisher-name><![CDATA[Pontificia Universidad Católica de Ecuador]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sturla]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Frascaroli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Santiso]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Crosbie]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Ursino]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Amato]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Luminal B. Factor pronóstico y predictivo del Ki67]]></article-title>
<source><![CDATA[Rev Argent Mastol]]></source>
<year>2018</year>
<volume>36</volume>
<numero>133</numero>
<issue>133</issue>
<page-range>101-15</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
